We are live on
!
Find out more
DGM
Darwin Global Management Portfolio holdings
AUM
$3.77B
1-Year Est. Return
307.72%
This Fund
S&P 500
This Quarter
Est. Return
+37.19%
1 Year Est. Return
+307.72%
3 Year Est. Return
+2,873.14%
5 Year Est. Return
+48,315.58%
10 Year Est. Return
–
AUM
$859M
AUM Growth
+$108M
(+14%)
Cap. Flow
+$44.8M
Cap. Flow
% of AUM
5.22%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
17
New
5
Increased
1
Reduced
3
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$276M |
| 2 |
Insmed
INSM
|
+$137M |
| 3 |
Geron
GERN
|
+$93.2M |
| 4 |
Corbus Pharmaceuticals
CRBP
|
+$13.7M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$5.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUVL
Nuvalent
NUVL
|
+$108M |
| 2 |
Biohaven
BHVN
|
+$80.8M |
| 3 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$78.6M |
| 4 |
Beam Therapeutics
BEAM
|
+$70M |
| 5 |
Apogee Therapeutics
APGE
|
+$55.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cytokinetics
CYTK
$10.9B
| $246M | 28.63% |
+4,575,558
| New | +$276M |
|
|
2
Insmed
INSM
$23.5B
| $237M | 27.58% |
+3,541,095
| New | +$137M |
|
3
Vaxcyte
PCVX
$8.12B
| $164M | 19.07% |
2,080,946
-669,858
| -24% | -$45.6M |
|
|
4
Geron
GERN
$924M
| $106M | 12.35% |
+23,915,480
| New | +$93.2M |
|
5
Keros Therapeutics
KROS
$211M
| $68.8M | 8% |
1,525,902
+89,952
| +6% | +$4.83M |
|
|
6
Corbus Pharmaceuticals
CRBP
$167M
| $14.3M | 1.66% |
+325,140
| New | +$13.7M |
|
7
Spyre Therapeutics
SYRE
$8.7B
| $10.3M | 1.19% |
452,040
-21,160
| -4% | -$714K |
|
|
RNAM
8
DELISTED
Avidity Biosciences
RNAM
| $8.11M | 0.94% |
+200,000
| New | +$5.74M |
|
|
ELEV
9
DELISTED
Elevation Oncology
ELEV
| $4.81M | 0.56% |
1,916,290
-416,638
| -18% | -$1.57M |
|
|
10
Apogee Therapeutics
APGE
$10.1B
| – | – |
-832,198
| Closed | -$55.3M |
|
|
11
Beam Therapeutics
BEAM
$2.83B
| – | – |
-2,119,598
| Closed | -$70M |
|
|
12
Biohaven
BHVN
$2.32B
| – | – |
-1,476,974
| Closed | -$80.8M |
|
13
Merck
MRK
$315B
| – | – |
-79,600
| Closed | -$10.5M |
|
|
NUVL
14
DELISTED
Nuvalent
NUVL
| – | – |
-1,436,964
| Closed | -$108M |
|
|
TRML
15
DELISTED
Tourmaline Bio
TRML
| – | – |
-465,000
| Closed | -$10.6M |
|
16
Xencor
XNCR
$1.3B
| – | – |
-1,109,650
| Closed | -$24.6M |
|
|
ALPN
17
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-1,982,016
| Closed | -$78.6M |
|
Similar funds
VVP
ABC
SCA
ACH
GL
VA
GCC
SB
Darwin Global Management's Q2 2024 Portfolio in Review
As of Q2 2024, Darwin Global Management held 17 positions worth $859M, up 14% from $751M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Darwin Global Management deployed $44.8M of net new capital in Q2 2024, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Cytokinetics: 4,575,558 shares worth $246M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Vaxcyte, an estimated $45.6M trimmed.
- Darwin Global Management's largest Q2 2024 buy was Cytokinetics: 4,575,558 shares worth $246M.
- Darwin Global Management added most to Keros Therapeutics in Q2 2024, an estimated $4.83M increase.
- Darwin Global Management's biggest Q2 2024 reduction was Vaxcyte, cutting an estimated $45.6M.
- Darwin Global Management fully exited Nuvalent in Q2 2024, selling an estimated $108M.
- Darwin Global Management's ten largest holdings make up 100% of its $859M portfolio in Q2 2024.
- Darwin Global Management opened 5 new positions and closed 8 in Q2 2024.
- Darwin Global Management's portfolio value rose 14% quarter-over-quarter to $859M.
Based on Darwin Global Management's 13F filing for Q2 2024, filed 14 Aug 2024.